Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor

AbbottAbbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. Since CE Mark approval, adoption of the device has been strong and implants have occurred in 10 countries across Europe. The Confirm Rx ICM is designed to continuously monitor a patient's heart rhythm and proactively transmit information via the myMerlinTM mobile app, allowing physicians to follow their patients remotely and accurately diagnose arrhythmias.

With the launch of the Confirm Rx ICM in European CE Mark countries, Abbott has established a new paradigm in the connectivity of cardiac devices by incorporating wireless technology, which allows the ICM to communicate directly and securely to the app downloaded onto a patient's smartphone. Traditional remote monitoring has required bulky handheld or bedside transmitters, which limit patient mobility. The new interactive myMerlin mobile app replaces these passive transmitters and empowers patients to participate in their own care.

In addition to patient convenience, the device is slimmer than currently available ICMs. The Confirm Rx ICM also offers intuitive one-touch indication-based programming, and remote monitoring via the Merlin.netTM Patient Care Network, making the technology convenient for clinicians involved in procedure and follow up.

"The Confirm Rx ICM device will be an important tool for diagnosing patients with suspected arrhythmias, such as those who have experienced fainting or palpitations," said Georg Nölker, M.D., head of electrophysiology at the Herz-und Diabeteszentrum NRW, Ruhr-University of Bad Oeynhausen, Germany. Dr. Nölker was one of the first physicians to implant the Confirm Rx ICM after it received CE Mark. "The simple insertion procedure and small device size make this technology convenient for both patients and providers. Patients can record symptoms directly on their smartphone without the need for a bedside transmitter or separate activator."

Christopher Piorkowski, M.D., head of the Department of Electrophysiology at the University of Dresden Heart Center in Dresden, Germany, and one of the first implanters, added: "The Confirm Rx ICM will be particularly useful in monitoring for atrial fibrillation in my patients with paroxysmal AF, following AF ablation and with stroke of an unknown cause. It allows an objective way to quantify AF events to guide treatment decisions. The smartphone compatibility engages patients and allows better compliance to remote monitoring through a simple and intuitive user interface. This allows clinic staff to reduce follow-up burden and focus on reviewing transmitted data for AF."

The myMerlin mobile app, available in over 35 languages, makes it easy for patients to stay connected to their physicians. Patients can record their symptoms on their own smartphone and specify events such as fainting or if they experience a fast heart rate. Patients can also confirm their data was transmitted to their physician and get automatic alerts when they have missed a scheduled transmission, saving the clinic from having to follow up with the patient. The device also offers secure transmission of patient data. Recently, Abbott's Merlin.net Patient Care Network received one of the medical device industry's first Service Organization Control certifications (SOC2 certification), further confirming the safety and security of the company's remote monitoring network.

"Incorporating wireless technology directly into our devices enhances the quality of remote monitoring and patient compliance," said Mark D. Carlson, M.D., chief medical officer of Abbott's cardiac arrhythmias and neuromodulation businesses. "The Confirm Rx ICM addresses a broad range of indications, such as syncope, palpitations and atrial fibrillation. The technology has been designed with robust data privacy and security measures to ensure peace of mind for both patients and providers."

Currently the Confirm Rx ICM is available in select countries in Europe, with full European release expected during the second quarter of 2017. The device is currently under review by the U.S. Food and Drug Administration. The estimated 2017 worldwide insertable cardiac monitor market is approximately $800 million and is growing by more than $100 million a year.

About Abbott
At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Most Popular Now

Digital Games Improve Mental Health …

Digital games can effectively teach refugee children much-needed skills - including a new language, cognitive skills, and coding - while also improving their mental health, finds research by New York...

Transforming eHealth into a Political an…

eHealth has quickly become a symbol of the democratization of healthcare, as well as an opportunity to meet the challenges caused by an ageing society, the epidemic of non-communicable and...

Philips Expands its uGrow Digital Parent…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has acquired Health & Parenting Ltd, a leading London-based developer of healthcare and family-related...

Digital Health Ambitions in East Ireland…

St Michael’s Hospital achieved a significant milestone in East Ireland's journey towards digitally enabled healthcare last week by going live with an electronic patient management system in its Emergency Department...

Roche Acquires mySugr to Form a Leading …

Roche (SIX: RO, ROG; OTCQX: RHHBY) and mySugr have signed an agreement under which Roche acquired all shares of mySugr GmbH. Counting more than one million users globally, mySugr is...

RELIEF Project Launches a Call for Tende…

The RELIEF project, coordinated by BravoSolution Spain, is looking for innovative ICT solutions to improve the self-management of chronic pain patients. The call for tenders is now open until the...

Saving Lives with IoT Technology

Tejre Tobiassen suffered from a cardio arrest. During his rehabilitation, Tejre came up with the idea of an intelligent wearable that could help prevent cardio arrest and other life threatening...

Self-Driving Cars may Soon Be Able to Ma…

Can a self-driving vehicle be moral, act like humans do, or act like humans expect humans to? Contrary to previous thinking, a ground-breaking new study has found for the first...

Siemens Healthineers Now the Official Me…

The new season of the Bundesliga, Germany's national soccer league, marks the start of a three-year partnership between Siemens Healthineers and the renowned championship team FC Bayern Munich. From July...

Researchers Study Link between Pokémon G…

Pokémon GO's worldwide release sent crowds hiking through parks, meandering into streets and walking for miles in search of Pokémon, those cute little digital characters that appear in real locations...

The Universitat Oberta de Catalunya (UOC…

This Wednesday, the Universitat Oberta de Catalunya (UOC) launched the first academic centre in southern Europe specializing in eHealth, the eHealth Center, at an act held in the Sala Europa...

Wirral University Teaching Hospital impl…

Blood cancer patients are receiving the very best care at Wirral University Teaching Hospital (WUTH) supported by pioneering technology which is the first of its kind in the UK. Patient...